| Name | Cadonilimab |
|---|
| Description | Cadonilimab (AK104) is a targeting PD1/CTLA4 IgG1 scaffold Fc-engineered humanized antibody. Cadonilimab can be used for researching metastatic cervical cancer[1][2]. |
|---|---|
| Related Catalog | |
| Target |
PD1[1] |
| References |
[2]. Kaplon H, et al. Antibodies to watch in 2022. MAbs. 2022 Jan-Dec;14(1):2014296. |
| No Any Chemical & Physical Properties |